MULTISPECIFIC ENGINEERING
Accelerating multispecific antibody development for next-generation therapies
Advance your project from concept to optimized therapeutic lead with Alloy’s comprehensive multispecific antibody development services.
Bring your multispecific programs to life with Alloy’s end-to-end monoclonal discovery and engineering capabilities
Partner with a proven team that delivers rank-ordered antibody candidates tailored to your target. Our comprehensive approach integrates various technologies and custom, proprietary workflows that ensure precise, high quality multispecific leads.
Rank-ordered multispecific candidates that match your target affinity, cross-reactivity, specificity, and functional activity design
Modular antibody domains
Discover high-quality fully human Fab, scFv, and VHH building blocks from our suite of ATX mice, including the ATX-CLC strain for common light chain antibodies or with our VHH library designed to be combined into highly manufacturable multispecifics.
Flexible multispecific production
State-of-the-art mammalian expression from ml to liter scale to enable full panel assessment from pre-clinical proof-of-concept to manufacturable evaluations.
Integrated functional pharmacology
Rapidly screen your multispecific panels in high-throughput biophysical and functional assays including cell killing, cytokine release, internalization, and more.
Off-the-shelf binding arms
Save critical months from your timeline by integrating one of our developed and validated off-the-shelf monoclonal antibodies against high value targets including tumor antigens, T-cell engagers, immunomodulation, and delivery shuttles.
mAbForge™ Multi
From binding arms to optimized multispecific leads in four weeks
mAbForge™ Multi is Alloy’s high velocity platform for multispecific antibody format scouting—enabling combinatorial screening of hundreds of multispecific clones across nearly any format or valency in just four weeks.
The platform accepts binding arms of any type—Fabs, ScFvs, VHHs, TCRs, protein domains —from Alloy’s discovery system or your own existing binders, using AI-guided design and micro-scale CHO expression to explore the full format space at once.
Partners receive a down-selected set of leads with complete purity, affinity, developability, and functional data, dramatically compressing the timeline from binding arm to optimized multispecific candidate.
Offering Details
Next-gen multispecific discovery with unmatched flexibility, precision, and speed
We’ve developed advanced workflows for multispecific engineering and screening that integrate format optimization, high throughput expression, biophysical characterization, and disease specific functional pharmacology screening.
Modular antibody discovery platforms for streamlined multispecific production
Alloy’s CLC & VHH platforms provide a foundation of modular building blocks that can be combined into an array of highly deveopable multispecific formats for rapid production and assessment.
ATX-CLC MOUSE
Our ATX-CLC common light chain mouse platform produces panels of high-quality, diverse antibodies that share a single light chain sequence. These domains can be combined in a range of multispecific formats while maintaining their native fragment antigen-binding (Fab) architecture, producing multispecifics with the drug-like properties of monoclonals.
IN VITRO VHH
Our in vitro VHH platforms for discovery of fully human, single domain antibodies with robust developability can be further combined with antibody domains to form diverse multispecifics.
Flexible, fit-for-purpose formats engineered by a team of experts
Starting with our modular monoclonal building blocks, including CLC & VHH domains, we leverage our high-throughput expression capabilities, mAbForge Multi™, to build out diverse panels of multispecifics combining different monoclonal pairs in different orientations. Based on our partner’s target product profile, our experienced teams can further incorporate different orientations, valencies, and Fc modifications where appropriate.
State-of-the-art transient and stable expression supports production of mg-to-gram scale of any multispecific format.
All multispecific candidates undergo rigorous derisking and validation for purity, manufacturablity, and drug-like properties prior to functional testing to ensure that your hits translate to developable drugs.
Integrated functional testing to rapidly identify your therapeutic lead
At Alloy, we integrate biophysical and functional testing into our antibody discovery and multispecific engineering workflows to streamline hit selection and reduce your program timelines. We work with our partners to develop a customized assay cascade that delivers an optimized multispecific for therapeutic development.
Streamline hit Selection with:
- Antibody-dependent cellular cytotxocity
- T-cell killing
- Cytokine release assay
- Antibody-dependent cellular phagocytosis
- Reporter cell lines
- Cellular internalization
Shave months off of your timeline by licensing one of our validated off-the-shelf monoclonal binding arms
Alloy offers a variety of well-characterized monoclonal binding arms against high-value antigens including T-cell engagers, delivery shuttle targets, and other targets across oncology and immunology that can be incorporated into your multispecific program to accelerate and de-risk development. Most antibodies available for license are built on our CLC or VHH technologies making them highly modular for combining with novel targeting arms.
target classes
- Cell engagers
- Immune modulators
- Delivery
- Tumor targets
VHH Libraries
Fully human VHH libraries for next-generation binder discovery
Alloy’s fully human VHH single-domain antibody libraries combine phage- and yeast-display selection with our PerformAb platform to identify high-affinity binders against even the most challenging multispan membrane protein targets. Built on clinically validated human scaffolds with CDR diversity curated from over 2.9 billion human donor sequences, our libraries are engineered from the ground up for solubility, developability, and stability.
Partners receive a complete biochemical, functional, and developability data package in as little as two months—with binders ready to deploy across multispecific formats, radioligand therapies, and cell therapy applications.
TCE OPTIMIZATION
Fully integrated from concept to optimized TCE
Effective T-cell engagers require binding arm geometry, valency, and potency to work in concert. Alloy brings together clinically validated anti-CD3 building blocks engineered for best-in-class developability, high-velocity multispecific production and integrated functional characterization in a single workflow, enabling TCE optimization tailored to your target product profile.
Start your next multispecific campaign with us
Launch your campaign with a customized approach to engineering that generates multispecific you can bring to the clinic.
Explore our additional capabilities and services for your therapeutic success
Learn more about our full suite of services and offerings designed to accelerate your path from target to clinic.
